New breakthrough! China's new inactivated coronavirus vaccine approved for clinical trials
The reporter learned on the 14th from the State Council Joint Prevention and Control Mechanism Scientific Research Group that two of our new inactivated coronavirus vaccines were granted clinical trial licenses by the State Drug Administration for the merger of the first and second phases, and became the first batch of new inactivated coronavirus vaccines to receive clinical research approvals . The two inactivated vaccines were developed by Sinopharm Group Wuhan Biological Products Research Institute and Beijing Kexing Zhongwei Biotechnology Co., Ltd. jointly with relevant scientific research institutions. Inactivated vaccine is a vaccine that kills pathogenic microorganisms but still maintains its immunogenicity. It has the advantages of mature production technology, controllable quality standards, and wide protection scope. China's vaccine emergency research is currently proceeding in accordance with five technical routes: inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, live attenuated influenza virus vector vaccines, and nucleic acid vaccines. Prior to this, the adenovirus vector vaccine of the Academy of Military Medical Sciences of the Academy of Military Sciences has been approved for clinical trials.